Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

胶质瘤 嵌合抗原受体 抗原 免疫疗法 癌症研究 表皮生长因子受体 生物 单克隆抗体 干细胞 抗体 免疫系统 免疫学 受体 细胞生物学 生物化学
作者
Richard A. Morgan,Laura A. Johnson,Jeremy L. Davis,Zhili Zheng,Kevin Woolard,Elizabeth A. Reap,Steven A. Feldman,Nachimuthu Chinnasamy,Chien-Tsun Kuan,Hua Song,Wei Zhang,Howard A. Fine,Steven A. Rosenberg
出处
期刊:Human Gene Therapy [Mary Ann Liebert, Inc.]
卷期号:23 (10): 1043-1053 被引量:302
标识
DOI:10.1089/hum.2012.041
摘要

No curative treatment exists for glioblastoma, with median survival times of less than 2 years from diagnosis. As an approach to develop immune-based therapies for glioblastoma, we sought to target antigens expressed in glioma stem cells (GSCs). GSCs have multiple properties that make them significantly more representative of glioma tumors than established glioma cell lines. Epidermal growth factor receptor variant III (EGFRvIII) is the result of a novel tumor-specific gene rearrangement that produces a unique protein expressed in approximately 30% of gliomas, and is an ideal target for immunotherapy. Using PCR primers spanning the EGFRvIII-specific deletion, we found that this tumor-specific gene is expressed in three of three GCS lines. Based on the sequence information of seven EGFRvIII-specific monoclonal antibodies (mAbs), we assembled chimeric antigen receptors (CARs) and evaluated the ability of CAR-engineered T cells to recognize EGFRvIII. Three of these anti-EGFRvIII CAR-engineered T cells produced the effector cytokine, interferon-γ, and lysed antigen-expressing target cells. We concentrated development on a CAR produced from human mAb 139, which specifically recognized GSC lines and glioma cell lines expressing mutant EGFRvIII, but not wild-type EGFR and did not recognize any normal human cell tested. Using the 139-based CAR, T cells from glioblastoma patients could be genetically engineered to recognize EGFRvIII-expressing tumors and could be expanded ex vivo to large numbers, and maintained their antitumor activity. Based on these observations, a γ-retroviral vector expressing this EGFRvIII CAR was produced for clinical application.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
111发布了新的文献求助10
刚刚
Autumn完成签到,获得积分10
1秒前
hh发布了新的文献求助10
1秒前
王人捷完成签到,获得积分0
1秒前
舒服的尔曼完成签到,获得积分10
2秒前
斯文败类的应助被王德荣采纳,获得10
2秒前
海鸥吃薯条完成签到,获得积分10
2秒前
风趣从霜完成签到,获得积分10
2秒前
lili完成签到,获得积分10
3秒前
syvshc的应助被秋落木采纳,获得10
3秒前
咔咔嚓嚓完成签到 ,获得积分10
4秒前
4秒前
4秒前
4秒前
lilylucky完成签到,获得积分10
5秒前
5秒前
谭dddd发布了新的文献求助10
6秒前
molihuakai的应助被表弟慢热手采纳,获得10
6秒前
小二郎的应助被表弟慢热手采纳,获得10
7秒前
hh完成签到,获得积分20
7秒前
wujiaman345完成签到,获得积分10
8秒前
8秒前
8秒前
Voyager发布了新的文献求助10
8秒前
samo发布了新的文献求助10
8秒前
8秒前
SciGPT的应助被elmo采纳,获得10
8秒前
勤恳思天完成签到,获得积分10
9秒前
9秒前
小二郎的应助被科研通管家采纳,获得10
9秒前
在水一方的应助被科研通管家采纳,获得10
9秒前
molihuakai的应助被科研通管家采纳,获得10
10秒前
哈哈完成签到 ,获得积分10
10秒前
科目三的应助被科研通管家采纳,获得10
10秒前
ding的应助被科研通管家采纳,获得10
10秒前
阮范我吃的应助被科研通管家采纳,获得30
10秒前
OK的应助被阳光雨堂采纳,获得50
10秒前
明理的荔枝完成签到,获得积分10
10秒前
情怀的应助被科研通管家采纳,获得10
10秒前
所所的应助被科研通管家采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187533
求助须知:如何正确求助?哪些是违规求助? 9575604
关于积分的说明 21842148
捐赠科研通 7785275
什么是DOI,文献DOI怎么找? 3434996
关于科研通互助平台的介绍 2559428
邀请新用户注册赠送积分活动 2481898